Bovine Colostrum and Sodium Butyrate on Gut Microbiota and Intestinal-Liver Axis in Weaned Piglets
Dietary supplementation with dried bovine colostrum or sodium butyrate selectively alters gut microbiota composition and hepatic metabolic markers in weaned piglets, but effect magnitude is limited and direct human clinical translation is not supported by this study.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Gut microbiota composition | D | ▲ Favorable | Sem IC 95% ou tamanho de efeito padronizado reportado; n=6/grupo | 1 |
| Hepatic metabolic markers (gut-liver axis) | D | ▲ Favorable | Sem IC 95% ou tamanho de efeito padronizado reportado; n=6/grupo | 1 |
| Intestinal microbial diversity | D | — Insufficient | Dados quantitativos completos não disponíveis no texto fornecido | 1 |
| Body weight gain | D | — Insufficient | Dados quantitativos completos não disponíveis no texto fornecido | 1 |
| Intestinal inflammatory markers | D | — Insufficient | Dados quantitativos completos não disponíveis no texto fornecido | 1 |
Context
Weaning in swine represents a critical window of microbial reorganization with physiological parallels to the human neonatal and pediatric intestine. Nutritional interventions at this stage may modulate microbiota composition and the gut-liver axis. Evidence on bovine colostrum and butyrate in this context remains partially inconsistent and requires adequately powered controlled studies.
What the study showed
The study identified alterations in gut microbiota composition and hepatic metabolic parameters associated with both interventions; however, the available full text does not report absolute numbers, confidence intervals, or standardized effect sizes for primary outcomes. The general direction of effects was favorable for both interventions regarding intestinal and hepatic health markers, but the absence of complete quantitative data prevents any statement about magnitude. No adverse effects were reported. Direct comparison between colostrum and butyrate was not the primary focus of the design.
How it was done
Controlled animal experimental study (piglet, swine model) with a 28-day duration (day 28 to day 56 of life). Eighteen piglets were randomly assigned to 3 groups (n=6 per group) in individual metabolic cages under controlled environmental conditions. Feeding followed a standardized protocol (2% body weight/day, twice daily) with pre-starter and starter feed per Pluske et al.
Effect magnitude
The available full text does not provide standardized effect sizes (SMD, RR, OR) with 95% CI for primary outcomes; magnitude assessment is hampered by the extremely small n (n=6 per group), which provides insufficient statistical power to detect clinically relevant differences.
Limitations
Sample size is critically small (n=6 per group, n=18 total), compromising statistical power and generalizability. The swine model shows high homology with humans, but direct extrapolation to human clinical practice requires additional translational studies. The absence of risk-of-bias assessment using a standardized tool (RoB 2 or animal-study equivalent, e.g., SYRCLE) and lack of outcome assessor blinding represent potential bias sources. The 28-day observation period is short for assessing sustained effects.
In clinical practice
This study does not support clinical recommendations for the use of bovine colostrum or sodium butyrate in humans based on its results alone. Clinicians may treat these data as hypothesis-generating for future translational research. Clinical decisions should be based on level A or B evidence in human populations.
What is still missing
RCTs in humans (or at minimum animal models with adequately powered samples) are needed to evaluate clinically relevant outcomes (intestinal permeability, serum inflammatory markers, hepatic function) with extended follow-up and standardized high-depth microbiota sequencing.